Mersana Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Mersana Therapeutics (NASDAQ:MRSN), a clinical-stage biopharmaceutical company, announced that President and CEO Anna Protopapas will present a company overview at the 39th Annual J.P. Morgan Conference on January 13, 2021, at 5:20 p.m. ET. The event will be held virtually, and a live webcast will be accessible on Mersana’s website, with an archived replay available for 90 days. Mersana focuses on developing antibody-drug conjugates (ADCs) aimed at treating cancers with high unmet medical needs, with notable candidates XMT-1536 and XMT-1592 currently in clinical studies.

CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that Anna Protopapas, President and Chief Executive Officer, will present a company overview at the 39^th Annual J.P. Morgan Conference being held virtually on Wednesday, January 13, 2021 at 5:20 p.m. ET.   

A live webcast of the presentation will be available on the Investors & Media section of Mersana’s website at www.mersana.com. An archived replay will be available for approximately 90-days following the presentation.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, XMT-1536, is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early stage programs include XMT-1660, a B7-H4 targeting ADC, as well as XMT-2056, a STING-agonist ADC developed using the Company’s Immunosynthen platform. In addition, multiple partners are using Mersana’s Dolaflexin platform to advance their ADC pipelines.

Contact:
Investor & Media Contact
Sarah Carmody
617-844-8577
scarmody@mersana.com 

FAQ

When will Mersana Therapeutics present at the J.P. Morgan Conference?

Mersana Therapeutics will present at the J.P. Morgan Conference on January 13, 2021, at 5:20 p.m. ET.

How can I watch Mersana Therapeutics' presentation live?

The presentation will be available via a live webcast on Mersana's website.

What is the focus of Mersana Therapeutics?

Mersana Therapeutics focuses on developing antibody-drug conjugates (ADCs) for cancer treatment.

What are the lead product candidates of Mersana Therapeutics?

Mersana's lead product candidates include XMT-1536 for ovarian cancer and NSCLC adenocarcinoma, and XMT-1592 targeting NaPi2b-expressing tumors.

How long will the archived presentation be available?

The archived presentation will be available for approximately 90 days after the live event.